Novartis agreed to acquire Excellergy, a next-generation anti-IgE biotech, in a transaction valued at up to $2 billion in upfront and milestone payments. The deal is designed to extend Novartis’ allergy franchise as Xolair faces biosimilar competition, with Exl-111 leading the strategy as an effector cell response inhibitor (ECRI) in Phase I. The article describes Exl-111’s mechanism as targeting receptor-bound IgE to achieve faster and deeper suppression of IgE signaling and downregulation of FcεRI—aiming to improve onset and symptom control beyond conventional anti-IgE approaches. The acquisition is expected to close in the second half of 2026, subject to regulatory approvals and customary closing conditions. Executives positioned the move as a portfolio reinforcement in immunology and allergy, while the early-stage entry also signals Novartis’ preference for platform-anchored assets rather than only late-stage molecules.